Retatrutide appears to be a new treatment in the fight against obesity. This novel drug, categorized as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in clinical trials. By activating these receptors, Retatrutide reduces hunger pangs, {promotesenergy expenditure, and ultimately leads to significant weight loss. While resear